The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...

FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a ...

The nerve pathway was 19 times out of 20 in the subpiriformis canal. In all cases the pathway was identical, with an oblique and vertical portion running down through the ischio-trochanteric channel.